IL17A and psoriasis: In addition to TNF-α inhibitors, biologics approved for moderate-to-severe psoriasis include IL-12/23 inhibitors (Ustekinumab), IL-17 inhibitors (Ixekizumab, Secukinumab, Brodalumab, Bimekizumab), and IL-23 inhibitors (Guselkumab, Risankizumab, Tildrakizumab) (23).